New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
11:32 EDTLH, SQNM, ILMN, PKILabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
News For LH;SQNM;ILMN;PKI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
06:45 EDTLHLabCorp removed from short-term buy list at Deutsche Bank
Subscribe for More Information
September 26, 2014
10:09 EDTLHHigh option volume stocks
Subscribe for More Information
September 25, 2014
09:13 EDTLHOn The Fly: Pre-market Movers
HIGHER: LipoScience (LPDX), up 63% after agreeing to be acquired by LabCorp (LH) for $5.25 per share in cash... Magnum Hunter (MHR), up 12.5% after announcing that throughput volumes on Eureka Hunter's gas gathering pipeline system have increased to about 316,500 MMBtu per day... Jabil Circuit (JBL), up 4.7% following its report of better than expected fourth EPS and revenue... JD.com (JD), up 0.7% after the stock was initiated with an Outperform rating at Macquarie. LOWER: Yahoo (YHOO), down 0.6% after RBC Capital downgraded its rating on the stock to Sector Perform from Outperform, saying the risk/reward is less attractive following Alibaba's (BABA) initial public offering... HB Fuller (FUL), down 15% after reporting quarterly results and guidance that missed analyst estimates... Omnova Solutions (OMN), down 10.8% after its Q3 adjusted EPS missed expectations... Pacira Pharmaceuticals (PCRX), down 9.2% after receiving an FDA warning letter over certain promotional materials on Exparel.
07:02 EDTLHLabCorp acquires LipoScience
LabCorp (LH) and LipoScience (LPDX) announced that they entered into a definitive merger agreement under which LabCorp would acquire LipoScience for a purchase price of $5.25 per share in cash, or a transaction value of $85.3M which represents a total enterprise value of approximately $63M. The Board of Directors of LipoScience has unanimously approved the agreement and recommended approval of the transaction by LipoScience’s stockholders. The transaction is subject to customary closing conditions including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and approval by LipoScience’s stockholders. The transaction is expected to close in Q4.
07:00 EDTLHLabCorp acquires LipoScience for $5.25 per share in cash
06:58 EDTLHLabCorp agrees to acquire LipoScience for $5.25 per share
Subscribe for More Information
06:56 EDTLHLabCorp to acquire LipoScience for $5.25 per share in all cash transaction
06:56 EDTLHLabCorp agrees to acquire LipoScience for $5.25 per share
Subscribe for More Information
September 22, 2014
07:05 EDTSQNMSequenom presents new data supporting accuracy of MaterniT21 test
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, presented patient clinical data substantiating the performance of its MaterniT21 PLUS noninvasive prenatal test in the laboratory. An ad hoc analysis of 185,000 samples from patients at high-risk for fetal chromosome aneuploidy demonstrated stable positivity rates for trisomy 21, 18 and 13, which mirror the positivity rates found in large studies on high-risk populations utilizing invasive diagnostic procedures. Additionally, Sequenom Laboratories reported performance results from clinical testing with the MaterniT21 PLUS test with Enhanced Sequencing Series. In the ad hoc analysis based on voluntary outcomes provided by clinicians, the estimated sensitivity for trisomy 21, 18 and 13 were 99.3%, 98.3% and 97.4% respectively, and the estimated specificity was >99.9% for all three trisomies. These clinical laboratory performance data are equivalent to those published in the clinical validation studies of the MaterniT21 test. Based on these performance metrics, Sequenom Laboratories estimates that the MaterniT21 PLUS test positive predictive value for trisomy 21, 18 and 13 were 99.0%, 97.6% and 92.8% respectively, and the negative predictive value was >99.9% for all three trisomies.
September 17, 2014
11:57 EDTSQNMSequenom management to meet with Maxim
Meetings to be held in New York on September 22 with a group luncheon also and in Boston on September 23 hosted by Maxim.
September 16, 2014
10:44 EDTSQNMSequenom lost Inter Partes Review to Ariosa, says Piper Jaffray
Subscribe for More Information
08:04 EDTLHLabCorp, ARCA Biopharma present GENETIC-AF poster at HFSoA meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use